United Therapeutics Corporation UTHR
NASDAQ · United States · Health Technology
$541.89+60.42 (+12.55%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.
District Court ruled that two of the six claims asserted against Liquidia are valid and infringedParties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics Corporation (NASDAQ:UTHR) on September 24, 2026, with a Sell rating and a $321 price target. The firm argues that shares trade above their historical valuation range while the core franchise shrinks, and that the market underestimates how hard the idiopathic pulmonary fibrosis (IPF) launch will […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.